Hematology & Oncology News & Issues
Facing continued downward pressure on reimbursement, oncologists are increasingly looking to forge closer affiliations with hospitals as a means of protecting their income and practice viability. Although not without obstacles, the 340B Drug Pricing Program provides an opportunity for hospitals to ensure the financial viability of physician practices, thereby ensuring the availability of high-quality services for the community. This article considers the 340B program as a mutually beneficial option for physicians and hospitals addressing new realities in the oncology market. Several models are discussed that allow both groups to maximize the benefits of the program.
